The FDA granted accelerated approval to GSK’s Nelkarmi (neladalkib) on November 17, 2026, introducing a new oral treatment for certain adults with previously treated ALK-positive non-small cell lung cancer (NSCLC). The medicine joins GSK’s portfolio following its acquisition of Nuvalent earlier this year. (Fierce Pharma’s coverage of the Nelkarmi approval)
| Item | Details |
|---|---|
| Company | GSK, through its acquisition of Nuvalent |
| Medicine | Nelkarmi (neladalkib) |
| Modality | Small-molecule ALK tyrosine kinase inhibitor |
| Administration | 150 mg orally once daily, with or without food |
| Approved indication | Previously treated locally advanced or metastatic ALK-positive NSCLC, subject to specified prior-treatment requirements |
| Approval pathway | FDA accelerated approval |
| Supporting study | Phase 1/2 ALKOVE-1 |
The approval covers patients who previously received alectinib as their only ALK tyrosine kinase inhibitor, or at least two ALK inhibitors and platinum-based chemotherapy, in the unresectable locally advanced or metastatic setting.
The supporting ALKOVE-1 study evaluated Nelkarmi without a comparator arm. The efficacy population used for approval included 222 previously treated patients, divided into two groups according to their treatment history.
Among 67 patients who had received alectinib as their only prior ALK inhibitor, the confirmed objective response rate was 49%. Among those who responded, 52% had responses lasting at least 12 months.
In the second group, comprising 155 patients previously treated with at least two ALK inhibitors and platinum-based chemotherapy, the response rate was 32%. Of the responders in that group, 51% maintained their response for at least 12 months.
The prescribing information includes warnings for liver, kidney and ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. (FDA’s approval announcement and clinical results)
Where Nelkarmi Fits in ALK-Positive Lung Cancer
In ALK-positive lung cancer, an abnormal ALK protein can continuously activate signals that support cancer-cell growth. Neladalkib inhibits ALK kinase activity. It was designed to address a range of resistance mutations, cross the blood-brain barrier, and selectively target ALK. These characteristics are relevant when earlier treatments lose effectiveness or the disease spreads to the brain.
Among ALKOVE-1 participants with measurable brain metastases at baseline, intracranial response rates were 55% in the prior-alectinib group and 26% in the more heavily treated group. These findings came from subgroups of 20 and 53 patients, respectively.
Because ALKOVE-1 had no comparator arm, it cannot establish whether Nelkarmi is more effective or better tolerated than another ALK inhibitor. The ongoing Phase 3 ALKAZAR trial compares neladalkib with Roche’s Alecensa (alectinib) in patients who have never received an ALK inhibitor. That population differs from the previously treated patients covered by this approval. (GSK’s Nelkarmi announcement)
Accelerated approval enables earlier access using measures reasonably likely to predict clinical benefit. For Nelkarmi, the supporting measures were tumor response and response duration. Further studies must confirm the anticipated clinical benefit. (FDA’s explanation of accelerated approval)
For patients whose treatment has stopped controlling their cancer, another option can be welcome news even when medicines targeting the same pathway already exist. I find the opportunity to continue treatment particularly meaningful. This approval makes an additional therapy available to eligible patients while further research continues. I hope more pharmaceutical companies keep investing in treatments that give people facing resistance additional opportunities to manage their disease.
For another development in targeted lung cancer treatment, read my previous analysis of Roche’s divarasib Phase 3 results in KRAS G12C-mutated NSCLC.


Leave a Reply